Bavarian Nordic enters collaboration agreement with GSK  

The Danish biopharmaceutical company has entered a collaboration agreement with GSK on production and marketing of Bavarian's smallpox vaccine Imvamune

Biopharmaceutical company Bavarian Nordic has entered a collaboration agreement with GlaxoSmithKline (GSK) on production and marketing of Bavarian Nordic's smallpox vaccine Imvamune. Under the contract GSK will produce and market Imvamune to a number of major international markets including North and South America, Japan, UK and France. At the Copenhagen Stock Exchange, Bavarian Nordic's shares broke through the index's 500 barrier as the news was released.


Bavarian Nordic was founded in 1994 and employs 100 people. The biopharmaceutical company leads the field in innovative vaccines to prevent infectious diseases. Concerning smallpox vaccines, Bavarian Nordic has development and supply contracts with a number of governments including Germany and the US. Partners include Epimmune, Gerolymatos, Impfstoffwerk Dessau-Tornau and Vaccine Solutions. The news is reported by financial newspaper Børsen online and on Bavarian Nordic's website.


Link > Bavarian Nordic 

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×